Mananya Kaewthawee Bristol-Myers Squibb (NYSE:BMY) is an American pharmaceutical company and one of the leaders in the oncology and cardiovascular markets. Thesis Since the end of 2022, the company's share price has fallen more than 36% before reaching the strong support level that caused a trend reversal in previous years. Before discussing the investment theses that make Bristol-Myers Squibb an attractive investment opportunity, I'd like to highlight the main reasons for the substantial decline in its pri ...

Key PointsBristol Myers Squibb plans to acquire Karuna Therapeutics for $14 billion. The company also expanded its psychiatric and neurological portfolio.It also offered $4.1 billion for cancer drug start-up RayzeBio.5 stocks we like better than Bristol-Myers SquibbBristol Myers Squibb Company NYSE: BMY is on a buying spree, announcing two acquisitions in less than a week. On December 22, the pharma giant said it was acquiring Karuna Therapeutics Inc. NASDAQ: KRTX for $330 per share in cash, for a total equ ...

Fusion Pharmaceuticals Inc.’s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday. Bristol Meyers Squibb Co. BMY, -1.61% announced plans Tuesday to acquire Rayze Bio Inc. RYZB, +100.85% for $4.1 billion. Meanwhile Eli Lilly & Co.’s LLY, ...

BALA CYNWYD, Pa., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. RayzeBio, Inc. (Nasdaq – RYZB) Under the terms of the agreement, RayzeBio will be acquired by Bristol Myers Squibb (NYSE:BMY) in an all-cash transaction valued at approximate ...

Key TakeawaysBristol Myers Squibb Co. announced it was buying RayzeBio Inc. for $4.1 billion, its second multibillion-dollar deal in less than a week.The agreement offers RayzeBio shareholders a 104% premium to their stock's closing price Friday, and shares of RayzeBio doubled in price after the news in Tuesday trading.Both recent company purchases expand Bristol-Myers Squibb's cancer-fighting portfolio.RayzeBio Inc. (RYZB) shares skyrocketed Tuesday after Bristol Myers Squibb Co. (BMY) said it was buying t ...

Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb's Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State of the Art Radiopharmaceutical Manufacturing Capabilities PRIN ...

PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors. RayzeBio is a clinical-stage radiopharmaceutical ther ...

Key TakeawaysU.S. equities continued their pre-Christmas rally in the last week of 2023, with the Dow, S&P 500, and Nasdaq all up.Intel received a $3.2 billion incentive deal from the Israeli government, and shares of the chipmaker rose.Bristol-Myers Squibb will pay $4.1 billion to buy RayzeBio as the drug maker moves to expand its cancer portfolio.Christmas may be over, but the so-called “Santa Claus rally” continued for U.S. equities at midday in the shortened final trading week of 2023. The Dow, S&P 500, ...

About this content About Andrew Kessel Andrew is a financial journalist with experience covering public companies in a wide breadth of industries, including tech, medicine, cryptocurrency, mining and retail. In addition to Proactive, he has been published in a Financial Times-owned newsletter covering broker-dealer firms and in the Columbia Misourian newspaper as the lead reporter focused on higher education. He got his start with an internship at Rolling Stone magazine.  Read more About the publisher Pr ...

Bristol Myers Squibb said on Tuesday it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business, marking the second large deal struck by the drugmaker in less than a week. With the deal, Bristol will gain access to RayzeBio's late-stage targeted cancer therapy, RYZ101, which works by combining radioactive particles that kill cells with molecules that attach themselves to the tumors.The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlim ...